Altimmune begins MOMENTUM obesity trial for Pemvidutide
Altimmune has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide in...
top of page
Browse by category
Search
Browse by tag
bottom of page